Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

European Urology: Editorial about REDUCE trial underlines value of dutasteride

May 25, 2010 By EurekAlert

Arnhem — On 8 May an editorial about the Reduction by
Dutasteride of Prostate Cancer Events (REDUCE) trial by Fritz H.
Schröder and Monique J. Roobol was published in the online
version of European Urology, the scientific journal of the
European Association of Urology (EAU).

The long-expected final report of the REDUCE trial appeared on
April 1, 2010 in the New England Journal of Medicine [1] together with a commentary entitled ‘Chemoprevention of prostate
cancer’ by Dr Patrick Walsh. What were the noteworthy items of the
editorial?

  • The REDUCE trial, contrary to the Prostate Cancer Prevention
    Trial (PCPT) [2], is performed in men who would have been
    candidates for biopsy anyway because of PSA values of 2.5 –
    10 ng/ml, making the reduction of the chance of a positive biopsy
    of 23% clinically relevant.

  • The mechanism of dutasteride is not primarily prevention but
    the inhibition of growth of small, well differentiated cancers as a
    result of the intracellular reduction of 5a-dihydrotestosterone
    (DHT). This mechanism which results in the prevention of disease
    progression is called ‘tertiary prevention’ and in this setting can
    be seen as treatment of minimal disease. This effect is seen in
    spite of the simultaneous, up to 40 times increase in testosterone
    (T) [3]. It remains unclear why the rise in T does not prevent the
    effect of the reduction in DHT.

  • The report indicates a small difference in cardiovascular side
    effects in disadvantage of dutasteride. The long-term general
    health effects obviously remain unknown at this time.

  • Unanswered issues: is dutasteride useful in reducing
    unnecessary biopsies and does it help to selectively identify
    aggressive disease? The reported data show that in men with an
    indication of periodic biopsies the reduction in the detection of
    potentially over-diagnosed cancers is 28.2% (table 3 in [1]).

  • More detailed analyses are warranted. Extended follow-up to
    monitor, for example, the outcome of relevant endpoints such as
    delayed diagnosis of aggressive cancers, progression to metastatic
    disease and disease-specific mortality in comparison to the control
    population will be of great scientific value in spite of the
    unblinding of the trial and should therefore have top
    priority.

SOURCE

Related Articles Read More >

TE Connectivity opens global medical device prototyping center in Ireland
Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech